The {pharmaceutical sector is rapidly exploring novel treatment strategies for obesity , and the arrival of semaglutide 10mg injectables represents a significant change. Clinicians are now evaluate the likely benefits and challenges associated with this increased strength product, particularly in comparison to existing standard semaglutide therapie